Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.

Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.

As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.

Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com


  • Ms Mary Harney, Non-executive Chair

    Mary is a cross sectoral specialist with two decades of board and C-suite Executive experience and a breadth of expertise across all aspects of business management in the biotechnology, pharmaceutical, health and agricultural spheres.

    She is currently Executive Director (acting) of the Global Health Alliance; Chair of unlisted oncology company, CTxONE and Executive Director of Mary Harney

    read more
  • Mr Damian Clarke-Bruce, CEO & Managing Director

    Damian is an experienced international healthcare executive, having worked in the
    biopharmaceutical and healthcare industries for over 25 years. Prior to joining Race

    Oncology, Damian served as the Global/US Executive Director of Marketing in Rare Disease for Pharming NV, a Netherlands/US Biopharma company.
    Damian’s career has also spanned multiple global pharmaceutical companies, including Celgene, Novartis & Biogen. He has held leadership roles within many executive teams across development/medical, market access and commercialization.

    read more
  • Dr Michelle Rashford, Chief Medical Officer

    Dr Michelle Rashford serves as Race Oncology’s Chief Medical Officer (CMO), and
    is an internationally experienced biopharmaceutical executive and former physician,
    with expertise in the successful development and commercialisation of
    pharmaceuticals across oncology, virology, and immunology.
    Her 25+ years of drug development experience spans large pharmaceuticals to
    smaller biotech companies and includes pre-clinical and clinical development,
    medical and regulatory affairs, and drug commercialisation.
    Prior to joining Race, Dr Rashford worked for Japanese pharmaceutical company
    Kyowa Kirin, where she has been the Head of Global Clinical Sciences.

    read more